Provvidenza Villari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Provvidenza Villari has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Maria Labate
SSD Diabetologia, ASST Franciacorta, Chiari, Italy, Italy
8 shared publications - Barbara Agosti
ASST Franciacorta, SSD Diabetologia, Viale Mazzini 4 25032 Chiari, Italy, Chiari, Italy, Italy
2 shared publications - Laura Giacomelli
ASST Franciacorta, SSD Diabetologia, Viale Mazzini 4 25032 Chiari, Italy, Chiari, Italy, Italy
2 shared publications - Lorenzo Moretti
ASST Garda, UOC Medicina Generale PO di Gavardo, Via Andrea Gosa 75, 25085 Gavardo, Italy
2 shared publications - Oladayo Adigun Oladeji
ASST Franciacorta, SSD Diabetologia, Viale Mazzini 4 25032 Chiari, Italy, Chiari, Italy, Italy
2 shared publications - Elena Cimino
ASST Franciacorta, SSD Diabetologia, Viale Mazzini 4 25032 Chiari, Italy, Chiari, Italy, Italy
1 shared publication
Latest Publications
- Open Access
- 17 November 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (11) , 223
Baseline Prediction of a Two-Year Reduction in a DIAL2-Derived Annual Cardiovascular Risk Estimate in Type 2 Diabetes: The DIAL-STEP Study
Background: Longitudinal changes in calculated cardiovascular risk estimates vary among individuals with type 2 diabetes. We investigated whether baseline clinical data predict a relative decrease of at least 10% in a DIAL2-derived calibrated one-year risk estimate (P1Y) over approximately two years. Methods: This retrospective single-centre prediction analysis included 324 patients with valid paired scores from 332 retained clinical records. The primary elastic net model excluded treatment-group indicators; random forest was a comparator. We used three repetitions of nested stratified five-fold validation, conditional patient bootstrap intervals, and a separate bootstrap repeating model development. Additional analyses examined simpler predictor sets, continuous changes and age-fixed estimates. Results: The criterion was met by 135/324 patients (41.7%). Mean test-fold area under the receiver operating characteristic curve (AUROC) was 0.783 for elastic net and 0.784 for random forest; average precision was 0.754 and 0.744, and Brier score 0.183 and 0.187. Averaged held-out elastic net predictions had AUROC 0.786 (conditional 95% interval 0.738–0.834) and calibration slope 0.990. A four-variable benchmark had mean AUROC 0.770, and a DIAL2-component benchmark 0.792. At fixed baseline age, 230/324 (71.0%) met the criterion; the separately tuned model had mean AUROC 0.739. Median individual score change was −0.10 percentage points. Conclusions: Baseline data discriminated subsequent calculated-score trajectories in internal validation. Most predictive information was contained in baseline score constituents, and classification was sensitive to age. The analysis does not establish clinical event reduction, causal drug effects or readiness for clinical use; independent validation and assessment of decision utility are required.
- 17 November 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (11) , 223
Open AccessBaseline Prediction of a Two-Year Reduction in a DIAL2-Derived Annual Cardiovascular Risk Estimate in Type 2 Diabetes: The DIAL-STEP Study
Background: Longitudinal changes in calculated cardiovascular risk estimates vary among individuals with type 2 diabetes. We investigated whether baseline clinical data predict a relative decrease of at least 10% in a DIAL2-derived calibrated one-year risk estimate (P1Y) over approximately two years. Methods: This retrospective single-centre prediction analysis included 324 patients with valid paired scores from 332 retained clinical records. The primary elastic net model excluded treatment-group indicators; random forest was a comparator. We used three repetitions of nested stratified five-fold validation, conditional patient bootstrap intervals, and a separate bootstrap repeating model development. Additional analyses examined simpler predictor sets, continuous changes and age-fixed estimates. Results: The criterion was met by 135/324 patients (41.7%). Mean test-fold area under the receiver operating characteristic curve (AUROC) was 0.783 for elastic net and 0.784 for random forest; average precision was 0.754 and 0.744, and Brier score 0.183 and 0.187. Averaged held-out elastic net predictions had AUROC 0.786 (conditional 95% interval 0.738–0.834) and calibration slope 0.990. A four-variable benchmark had mean AUROC 0.770, and a DIAL2-component benchmark 0.792. At fixed baseline age, 230/324 (71.0%) met the criterion; the separately tuned model had mean AUROC 0.739. Median individual score change was −0.10 percentage points. Conclusions: Baseline data discriminated subsequent calculated-score trajectories in internal validation. Most predictive information was contained in baseline score constituents, and classification was sensitive to age. The analysis does not establish clinical event reduction, causal drug effects or readiness for clinical use; independent validation and assessment of decision utility are required.
- Open Access
- 29 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9723
PCSK9 in the Immunometabolism of Type 2 Diabetes
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition reduces cardiovascular events in type 2 diabetes, while experimental studies implicate PCSK9 in immune activation, platelet function and organ-specific metabolism. Whether these mechanisms contribute clinically beyond atherogenic lipoprotein lowering remains uncertain. This critical narrative review integrates an original corpus of 108 appraised publications, with targeted additions during revision. It evaluates whether findings from different compartments and experimental perturbations can be transferred to particular treatments and clinical outcomes. Mechanistic evidence implicates receptor trafficking, intracellular cholesterol, mitochondrial stress and inflammatory signalling. Effects vary by cell type and compartment: local PCSK9 promotes injury in some models but preserves pancreatic, glomerular or cardiac function in others. Global knockout, tissue-specific deletion, extracellular antibodies and hepatic silencing are therefore distinct exposures. Human biomarker and imaging studies provide translational signals but generally cannot isolate direct effects from concomitant lipoprotein changes. Randomised antibody trials establish cardiovascular efficacy and an overall reassuring glycaemic profile, without demonstrating clinically meaningful glucose lowering. PCSK9 has broader immunometabolic functions, but the available evidence does not quantify an additional clinical benefit independent of atherogenic lipoprotein lowering. Tissue-specific mechanisms and causal mediation require further investigation.
- 29 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9723
Open AccessPCSK9 in the Immunometabolism of Type 2 Diabetes
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition reduces cardiovascular events in type 2 diabetes, while experimental studies implicate PCSK9 in immune activation, platelet function and organ-specific metabolism. Whether these mechanisms contribute clinically beyond atherogenic lipoprotein lowering remains uncertain. This critical narrative review integrates an original corpus of 108 appraised publications, with targeted additions during revision. It evaluates whether findings from different compartments and experimental perturbations can be transferred to particular treatments and clinical outcomes. Mechanistic evidence implicates receptor trafficking, intracellular cholesterol, mitochondrial stress and inflammatory signalling. Effects vary by cell type and compartment: local PCSK9 promotes injury in some models but preserves pancreatic, glomerular or cardiac function in others. Global knockout, tissue-specific deletion, extracellular antibodies and hepatic silencing are therefore distinct exposures. Human biomarker and imaging studies provide translational signals but generally cannot isolate direct effects from concomitant lipoprotein changes. Randomised antibody trials establish cardiovascular efficacy and an overall reassuring glycaemic profile, without demonstrating clinically meaningful glucose lowering. PCSK9 has broader immunometabolic functions, but the available evidence does not quantify an additional clinical benefit independent of atherogenic lipoprotein lowering. Tissue-specific mechanisms and causal mediation require further investigation.
- Open Access
- 27 October 2026
- Published by MDPI AG in Preprints.org
Defining and Predicting Inadequate Weight Response to Oral Semaglutide
Background: Oral semaglutide produces substantial average weight loss, but the term non-responder combines clinically different situations. Failure to cross a numerical threshold may reflect limited treatment exposure, intolerance, a slow trajectory or persistently inadequate efficacy. Identifying these situations is particularly important when evidence from diabetes doses is applied to oral obesity treatment. Objective: To critically examine definitions of inadequate weight response to oral semaglutide and assess whether baseline characteristics or early treatment patterns identify patients likely to derive less weight benefit. Methods: A narrative synthesis drew on searches of PubMed, Embase, Web of Science and CENTRAL, supplemented by primary trial appendices and conference materials. Evidence was interpreted separately by oral dose, diabetes status, follow-up, analysis population and publication type. Observed responder counts were distinguished from model-based estimates. No quantitative pooling was performed. Results: The apparent frequency of weight loss below 5% varied substantially with population, dose and denominator. At the end of OASIS 4, 40/192 participants with observed in-trial measurements and 20/157 with on-treatment measurements remained below 5% loss. These proportions do not establish biological resistance. Baseline sex and body weight showed exploratory signals in OASIS 1, whereas age, BMI, diabetes duration and baseline HbA1c did not consistently distinguish weight response across studies. An OASIS 4 post hoc analysis associated early weight loss with subsequent trajectories, but participants below 5% loss at week 16 still achieved a mean 7.0% reduction at week 64. Behavioral and exposure models remain exploratory. Conclusions: Current evidence supports a time-dependent, treatment-specific assessment of inadequate weight response rather than a fixed baseline non-responder phenotype. Early trajectories inform expectations but do not validate an automatic stopping rule. Persistent low weight response should be described alongside achieved dose, administration, persistence, tolerability and other treatment outcomes.
- 27 October 2026
- Published by MDPI AG in Preprints.org
Open AccessDefining and Predicting Inadequate Weight Response to Oral Semaglutide
Background: Oral semaglutide produces substantial average weight loss, but the term non-responder combines clinically different situations. Failure to cross a numerical threshold may reflect limited treatment exposure, intolerance, a slow trajectory or persistently inadequate efficacy. Identifying these situations is particularly important when evidence from diabetes doses is applied to oral obesity treatment. Objective: To critically examine definitions of inadequate weight response to oral semaglutide and assess whether baseline characteristics or early treatment patterns identify patients likely to derive less weight benefit. Methods: A narrative synthesis drew on searches of PubMed, Embase, Web of Science and CENTRAL, supplemented by primary trial appendices and conference materials. Evidence was interpreted separately by oral dose, diabetes status, follow-up, analysis population and publication type. Observed responder counts were distinguished from model-based estimates. No quantitative pooling was performed. Results: The apparent frequency of weight loss below 5% varied substantially with population, dose and denominator. At the end of OASIS 4, 40/192 participants with observed in-trial measurements and 20/157 with on-treatment measurements remained below 5% loss. These proportions do not establish biological resistance. Baseline sex and body weight showed exploratory signals in OASIS 1, whereas age, BMI, diabetes duration and baseline HbA1c did not consistently distinguish weight response across studies. An OASIS 4 post hoc analysis associated early weight loss with subsequent trajectories, but participants below 5% loss at week 16 still achieved a mean 7.0% reduction at week 64. Behavioral and exposure models remain exploratory. Conclusions: Current evidence supports a time-dependent, treatment-specific assessment of inadequate weight response rather than a fixed baseline non-responder phenotype. Early trajectories inform expectations but do not validate an automatic stopping rule. Persistent low weight response should be described alongside achieved dose, administration, persistence, tolerability and other treatment outcomes.
- Open Access
- 19 October 2026
- Published by MDPI AG in Preprints.org
PCSK9 in the Immunometabolism of Type 2 Diabetes
PCSK9 inhibition reduces cardiovascular events in patients with type 2 diabetes, while experimental studies implicate PCSK9 in immune activation, platelet function and organ-specific metabolism. Whether these mechanisms contribute clinically beyond atherogenic lipoprotein lowering remains uncertain. This critical narrative review integrates 108 appraised publications identified through structured searches and supplementary retrieval. Mechanistic evidence supports roles involving LDLR, CD36, intracellular cholesterol, mitochondrial stress and inflammatory signalling. The effects vary by cell type and compartment: local PCSK9 can promote injury in some models but preserve pancreatic, glomerular or cardiac function in others. Global knockout, tissue-specific deletion, extracellular antibodies and hepatic silencing consequently cannot be treated as equivalent interventions. Human biomarker and imaging studies provide translational signals, but generally cannot separate direct effects from concomitant lipoprotein changes. Randomised antibody trials establish cardiovascular efficacy and an overall reassuring glycaemic profile during follow-up, without demonstrating a clinically meaningful glucose-lowering effect. PCSK9 therefore has immunometabolic functions beyond plasma LDL regulation, but the available evidence does not isolate or quantify an additional clinical benefit independent of reductions in atherogenic lipoproteins. Tissue-specific mechanisms and causal mediation require further investigation before broader therapeutic claims are justified.
- 19 October 2026
- Published by MDPI AG in Preprints.org
Open AccessPCSK9 in the Immunometabolism of Type 2 Diabetes
PCSK9 inhibition reduces cardiovascular events in patients with type 2 diabetes, while experimental studies implicate PCSK9 in immune activation, platelet function and organ-specific metabolism. Whether these mechanisms contribute clinically beyond atherogenic lipoprotein lowering remains uncertain. This critical narrative review integrates 108 appraised publications identified through structured searches and supplementary retrieval. Mechanistic evidence supports roles involving LDLR, CD36, intracellular cholesterol, mitochondrial stress and inflammatory signalling. The effects vary by cell type and compartment: local PCSK9 can promote injury in some models but preserve pancreatic, glomerular or cardiac function in others. Global knockout, tissue-specific deletion, extracellular antibodies and hepatic silencing consequently cannot be treated as equivalent interventions. Human biomarker and imaging studies provide translational signals, but generally cannot separate direct effects from concomitant lipoprotein changes. Randomised antibody trials establish cardiovascular efficacy and an overall reassuring glycaemic profile during follow-up, without demonstrating a clinically meaningful glucose-lowering effect. PCSK9 therefore has immunometabolic functions beyond plasma LDL regulation, but the available evidence does not isolate or quantify an additional clinical benefit independent of reductions in atherogenic lipoproteins. Tissue-specific mechanisms and causal mediation require further investigation before broader therapeutic claims are justified.
- Open Access
- 29 September 2026
- Published by MDPI AG in Preprints.org
Baseline Prediction of a Two-Year Reduction in Estimated Annual Cardiovascular Risk in Type 2 Diabetes: The DIAL-STEP Study
Background: Longitudinal changes in estimated cardiovascular risk vary across indi-viduals with type 2 diabetes. We investigated whether baseline clinical data predict a relative decrease of at least 10% in the DIAL2-derived calibrated one-year cardiovascular risk estimate (P1Y) over two years. Methods: This single-centre observational prediction analysis used data collected at ASST Mantova. Of 332 source records, 324 had valid P1Y estimates at baseline (T0) and two years (T2). Elastic net logistic regression and random forest were assessed with three repetitions of nested stratified five-fold cross-validation. We assessed discrimination, average precision, Brier score, and calibration of held-out predictions. Results: The response criterion was met in 135 of 324 patients (41.7%). Mean test-fold area under the receiver operating characteristic curve (AUROC) was 0.788 (fold SD 0.043) with elastic net and 0.780 (0.047) with random forest. Average precision was 0.755 and 0.740, and Brier score was 0.183 and 0.190. Elastic net without treatment group yielded AUROC 0.783. Averaged held-out elastic net predictions had AUROC 0.792 and calibration slope 0.978. At fixed baseline age, 230/324 (71.0%) met the reduction criterion; a separately validated elastic net had mean AUROC 0.751. Outcomes were changes in a computed risk estimate, not observed cardiovascular events. Conclusions: Baseline characteristics discriminated individuals with a two-year reduction in estimated annual risk in internal validation. Endpoint status was sensitive to the age term in DIAL2. These findings require validation in an independent cohort; model outputs cannot establish the effect of any therapy on clinical cardiovascular outcomes.
- 29 September 2026
- Published by MDPI AG in Preprints.org
Open AccessBaseline Prediction of a Two-Year Reduction in Estimated Annual Cardiovascular Risk in Type 2 Diabetes: The DIAL-STEP Study
Background: Longitudinal changes in estimated cardiovascular risk vary across indi-viduals with type 2 diabetes. We investigated whether baseline clinical data predict a relative decrease of at least 10% in the DIAL2-derived calibrated one-year cardiovascular risk estimate (P1Y) over two years. Methods: This single-centre observational prediction analysis used data collected at ASST Mantova. Of 332 source records, 324 had valid P1Y estimates at baseline (T0) and two years (T2). Elastic net logistic regression and random forest were assessed with three repetitions of nested stratified five-fold cross-validation. We assessed discrimination, average precision, Brier score, and calibration of held-out predictions. Results: The response criterion was met in 135 of 324 patients (41.7%). Mean test-fold area under the receiver operating characteristic curve (AUROC) was 0.788 (fold SD 0.043) with elastic net and 0.780 (0.047) with random forest. Average precision was 0.755 and 0.740, and Brier score was 0.183 and 0.190. Elastic net without treatment group yielded AUROC 0.783. Averaged held-out elastic net predictions had AUROC 0.792 and calibration slope 0.978. At fixed baseline age, 230/324 (71.0%) met the reduction criterion; a separately validated elastic net had mean AUROC 0.751. Outcomes were changes in a computed risk estimate, not observed cardiovascular events. Conclusions: Baseline characteristics discriminated individuals with a two-year reduction in estimated annual risk in internal validation. Endpoint status was sensitive to the age term in DIAL2. These findings require validation in an independent cohort; model outputs cannot establish the effect of any therapy on clinical cardiovascular outcomes.
- Open Access
- 20 September 2026
- Published by MDPI AG in Preprints.org
Efficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs
Background/Objectives: Orforglipron and danuglipron are the two most clinically advanced oral small-molecule (non-peptide) GLP-1 receptor agonists, sharing a common mechanism of action but markedly different regulatory outcomes — approval versus discontinuation. No existing review synthesizes their complete registrational evidence. Methods: We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science (inception to September 2026; PROSPERO-registered protocol) for phase 2/3 randomized controlled trials of orforglipron or danuglipron in adults with type 2 diabetes and/or obesity. Risk of bias was assessed with Cochrane RoB 2. Comparable trials were pooled using random-effects meta-analysis; clinically heterogeneous or non-comparable trials were synthesized narratively. Results: Of 505 records identified (286 after deduplication), 13 phase 2/3 randomized controlled trials met the registered eligibility criteria (10 orforglipron, 3 danuglipron); a further 17 reports (phase 1, mechanistic, or post hoc analyses of these trials) were retained only as contextual evidence. Of the 13 eligible trials, 9 (6 orforglipron phase 3, 3 danuglipron phase 2; N=9,693) were included in the quantitative synthesis, of which subsets sharing a common comparator were combined by random-effects meta-analysis (3 trials for HbA1c, 2 for body weight in type 2 diabetes); the remainder are reported as standalone estimates. Orforglipron produced a pooled HbA1c reduction of −1.14 percentage points versus placebo (95% CI −1.25 to −1.02; I²=0%) and superior glycemic control versus dapagliflozin and oral semaglutide. Weight loss varied by population: −9.10% in obesity without diabetes (single trial) and a pooled −6.54% in type 2 diabetes (95% CI −7.96 to −5.11; I²=49.8%, explained by background therapy). No hepatic safety signal was observed across 11,220 pooled orforglipron participants. Danuglipron showed comparable glycemic and weight efficacy but substantially higher, dose-dependent discontinuation (up to 72.7% in one arm), and its development was discontinued after a probable drug-induced liver injury case identified in a later, unpublished study. Conclusions: Despite a shared molecular target, orforglipron and danuglipron followed divergent clinical trajectories driven by differences in dosing regimen, tolerability, and hepatic safety rather than by pharmacodynamic efficacy, which was broadly comparable between the two molecules. These findings underscore that efficacy alone is an incomplete predictor of clinical success for oral small-molecule GLP-1 receptor agonists.
- 20 September 2026
- Published by MDPI AG in Preprints.org
Open AccessEfficacy and Safety of Oral Small-Molecule (Non-Peptide) GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity: A Systematic Review of the Complete Orforglipron and Danuglipron Clinical Development Programs
Background/Objectives: Orforglipron and danuglipron are the two most clinically advanced oral small-molecule (non-peptide) GLP-1 receptor agonists, sharing a common mechanism of action but markedly different regulatory outcomes — approval versus discontinuation. No existing review synthesizes their complete registrational evidence. Methods: We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science (inception to September 2026; PROSPERO-registered protocol) for phase 2/3 randomized controlled trials of orforglipron or danuglipron in adults with type 2 diabetes and/or obesity. Risk of bias was assessed with Cochrane RoB 2. Comparable trials were pooled using random-effects meta-analysis; clinically heterogeneous or non-comparable trials were synthesized narratively. Results: Of 505 records identified (286 after deduplication), 13 phase 2/3 randomized controlled trials met the registered eligibility criteria (10 orforglipron, 3 danuglipron); a further 17 reports (phase 1, mechanistic, or post hoc analyses of these trials) were retained only as contextual evidence. Of the 13 eligible trials, 9 (6 orforglipron phase 3, 3 danuglipron phase 2; N=9,693) were included in the quantitative synthesis, of which subsets sharing a common comparator were combined by random-effects meta-analysis (3 trials for HbA1c, 2 for body weight in type 2 diabetes); the remainder are reported as standalone estimates. Orforglipron produced a pooled HbA1c reduction of −1.14 percentage points versus placebo (95% CI −1.25 to −1.02; I²=0%) and superior glycemic control versus dapagliflozin and oral semaglutide. Weight loss varied by population: −9.10% in obesity without diabetes (single trial) and a pooled −6.54% in type 2 diabetes (95% CI −7.96 to −5.11; I²=49.8%, explained by background therapy). No hepatic safety signal was observed across 11,220 pooled orforglipron participants. Danuglipron showed comparable glycemic and weight efficacy but substantially higher, dose-dependent discontinuation (up to 72.7% in one arm), and its development was discontinued after a probable drug-induced liver injury case identified in a later, unpublished study. Conclusions: Despite a shared molecular target, orforglipron and danuglipron followed divergent clinical trajectories driven by differences in dosing regimen, tolerability, and hepatic safety rather than by pharmacodynamic efficacy, which was broadly comparable between the two molecules. These findings underscore that efficacy alone is an incomplete predictor of clinical success for oral small-molecule GLP-1 receptor agonists.
- Open Access
- 3 March 2026
- Published by MDPI AG in Endocrines
- Vol. 7 (1) , 8
Glycaemic and Cardiometabolic Effects of Oral Semaglutide in Patients Aged ≥65 Years with Type 2 Diabetes
Background: Older patients with type 2 diabetes mellitus (T2DM) are often undertreated because of concerns regarding hypoglycaemia and clinical heterogeneity. Although the evidence base for oral semaglutide is growing, data specifically in older adults remain relatively limited, particularly regarding long-term effectiveness and tolerability in routine practice. Methods: This observational study included 81 patients aged ≥65 years with T2DM treated with oral semaglutide for 12 months. Changes in glycaemic, anthropometric and cardiometabolic parameters were evaluated. The primary endpoint was the achievement of HbA1c < 7% at 12 months. Multivariable logistic regression was performed to identify baseline predictors of response. Results: HbA1c decreased from 7.75 ± 1.01% to 6.80 ± 0.88% after 12 months (p < 0.00001). Significant reductions were observed in body weight (−4.09 ± 4.42 kg, p < 0.00001), BMI (−1.50 ± 1.55 kg/m2, p < 0.00001) and waist circumference (−5.83 ± 4.71 cm, p < 0.00001). Improvements were also detected in lipid profile, blood pressure and visceral adiposity indices. No hypoglycaemic events were reported during follow-up. In multivariable analysis, baseline age, diabetes duration, baseline HbA1c and baseline VAI were not independently associated with the achievement of HbA1c < 7%; therefore, these baseline factors did not discriminate responders within our cohort (hypothesis-generating). Greater absolute HbA1c reductions were observed in patients with higher baseline HbA1c. Conclusions: In older patients with T2DM, oral semaglutide is associated with effective glycaemic control without hypoglycaemia and with a response largely independent of baseline clinical characteristics, supporting its use in elderly and clinically heterogeneous populations.
- 3 March 2026
- Published by MDPI AG in Endocrines
- Vol. 7 (1) , 8
Open AccessGlycaemic and Cardiometabolic Effects of Oral Semaglutide in Patients Aged ≥65 Years with Type 2 Diabetes
Background: Older patients with type 2 diabetes mellitus (T2DM) are often undertreated because of concerns regarding hypoglycaemia and clinical heterogeneity. Although the evidence base for oral semaglutide is growing, data specifically in older adults remain relatively limited, particularly regarding long-term effectiveness and tolerability in routine practice. Methods: This observational study included 81 patients aged ≥65 years with T2DM treated with oral semaglutide for 12 months. Changes in glycaemic, anthropometric and cardiometabolic parameters were evaluated. The primary endpoint was the achievement of HbA1c < 7% at 12 months. Multivariable logistic regression was performed to identify baseline predictors of response. Results: HbA1c decreased from 7.75 ± 1.01% to 6.80 ± 0.88% after 12 months (p < 0.00001). Significant reductions were observed in body weight (−4.09 ± 4.42 kg, p < 0.00001), BMI (−1.50 ± 1.55 kg/m2, p < 0.00001) and waist circumference (−5.83 ± 4.71 cm, p < 0.00001). Improvements were also detected in lipid profile, blood pressure and visceral adiposity indices. No hypoglycaemic events were reported during follow-up. In multivariable analysis, baseline age, diabetes duration, baseline HbA1c and baseline VAI were not independently associated with the achievement of HbA1c < 7%; therefore, these baseline factors did not discriminate responders within our cohort (hypothesis-generating). Greater absolute HbA1c reductions were observed in patients with higher baseline HbA1c. Conclusions: In older patients with T2DM, oral semaglutide is associated with effective glycaemic control without hypoglycaemia and with a response largely independent of baseline clinical characteristics, supporting its use in elderly and clinically heterogeneous populations.
- Open Access
- 9 January 2026
- Published by MDPI AG in Preprints.org
Glycaemic and Cardiometabolic Effects of Oral Semaglutide in Patients Aged ≥65 Years with Type 2 Diabetes
Background: Older patients with type 2 diabetes mellitus (T2DM) are often undertreated because of concerns regarding hypoglycaemia and clinical heterogeneity. Data on the effectiveness of oral semaglutide in this population remain limited. Methods: This observational study included 81 patients aged ≥65 years with T2DM treated with oral semaglutide for 12 months. Changes in glycaemic, anthropometric and cardiometabolic parameters were evaluated. The primary endpoint was achievement of HbA1c Results: HbA1c decreased from 7.75 ± 1.01% to 6.80 ± 0.88% after 12 months (p < 0.00001). Significant reductions were observed in body weight (−4.09 ± 4.42 kg, p < 0.00001), BMI (−1.50 ± 1.55 kg/m², p < 0.00001) and waist circumference (−5.83 ± 4.71 cm, p < 0.00001). Improvements were also detected in lipid profile, blood pressure and visceral adiposity indices. No hypoglycaemic events were reported during follow-up. In multivariable analysis, no baseline clinical or metabolic variable independently predicted achievement of HbA1c Conclusions: In older patients with T2DM, oral semaglutide is associated with effective glycaemic control without hypoglycaemia and with a response largely independent of baseline clinical characteristics, supporting its use in elderly and clinically heterogeneous populations.
- 9 January 2026
- Published by MDPI AG in Preprints.org
Open AccessGlycaemic and Cardiometabolic Effects of Oral Semaglutide in Patients Aged ≥65 Years with Type 2 Diabetes
Background: Older patients with type 2 diabetes mellitus (T2DM) are often undertreated because of concerns regarding hypoglycaemia and clinical heterogeneity. Data on the effectiveness of oral semaglutide in this population remain limited. Methods: This observational study included 81 patients aged ≥65 years with T2DM treated with oral semaglutide for 12 months. Changes in glycaemic, anthropometric and cardiometabolic parameters were evaluated. The primary endpoint was achievement of HbA1c Results: HbA1c decreased from 7.75 ± 1.01% to 6.80 ± 0.88% after 12 months (p < 0.00001). Significant reductions were observed in body weight (−4.09 ± 4.42 kg, p < 0.00001), BMI (−1.50 ± 1.55 kg/m², p < 0.00001) and waist circumference (−5.83 ± 4.71 cm, p < 0.00001). Improvements were also detected in lipid profile, blood pressure and visceral adiposity indices. No hypoglycaemic events were reported during follow-up. In multivariable analysis, no baseline clinical or metabolic variable independently predicted achievement of HbA1c Conclusions: In older patients with T2DM, oral semaglutide is associated with effective glycaemic control without hypoglycaemia and with a response largely independent of baseline clinical characteristics, supporting its use in elderly and clinically heterogeneous populations.